Global Nontuberculous Mycobacterial Infections Market to Reach US$18.3 Billion by 2030
The global market for Nontuberculous Mycobacterial Infections estimated at US$14.0 Billion in the year 2024, is expected to reach US$18.3 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Clarithromycin, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$7.1 Billion by the end of the analysis period. Growth in the Azithromycin segment is estimated at 2.9% CAGR over the analysis period.
The U.S. Market is Estimated at US$3.8 Billion While China is Forecast to Grow at 8.4% CAGR
The Nontuberculous Mycobacterial Infections market in the U.S. is estimated at US$3.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.
Why Are Nontuberculous Mycobacteria (NTM) Gaining Clinical Attention?
Infections caused by nontuberculous mycobacteria have become a growing concern due to increasing identification in patients with chronic lung conditions, such as bronchiectasis, COPD, or cystic fibrosis. These environmental bacteria are found in soil, water systems, and biofilms and can cause persistent, difficult-to-treat pulmonary infections. Increased awareness among pulmonologists, coupled with more frequent use of high-resolution imaging and sputum cultures, has led to a rise in confirmed diagnoses globally.
NTM infections can also occur in skin and soft tissue, lymph nodes, and disseminated in immunocompromised individuals. Clinical recognition has improved through updated guidelines that encourage suspicion in patients with unexplained respiratory symptoms and persistent nodular or bronchiectatic changes on CT scans. This heightened vigilance has driven more systematic screening and laboratory testing, making infection rates appear to rise even as actual incidence increases.
How Are Diagnostic and Treatment Innovations Improving Patient Outcomes?
Diagnostic methods for NTM are evolving beyond traditional culture-based techniques. Molecular assays, such as PCR and line probe assays, enable faster species identification and antimicrobial resistance detection. This precision allows clinicians to tailor antibiotic regimens early in therapy, improving treatment success. Research into novel biomarkers and advanced imaging techniques is helping differentiate active infection from colonization, addressing a key challenge in clinical management.
Therapeutic approaches now combine multiple antimycobacterial agents administered for long durations, often exceeding 12 months. Newer drugs-such as inhaled amikacin liposome suspension and oxazolidinones-offer targeted therapy with reduced systemic toxicity. Adjunct treatments, including airway clearance devices and pulmonary rehabilitation, support lung function and treatment adherence. Clinical trials are testing immunomodulatory agents to boost host response and reduce bacterial burden, with promising early-stage results.
What Care Models and Management Strategies Are Emerging?
Management of NTM infections increasingly relies on multidisciplinary care teams that include pulmonologists, infectious disease specialists, radiologists, and pharmacists. Comprehensive care hubs offer coordinated diagnostics, treatment initiation, monitoring of drug interactions, side effects, and adherence support. Telehealth tools and digital reminders are also being used to monitor long-term treatment compliance and track adverse effects remotely.
Patient education and support groups are gaining importance in treatment frameworks. Sustained patient engagement through digital platforms helps manage the emotional and logistical challenges of prolonged therapy. Health systems are beginning to develop NTM-specific registries that collect data on treatment outcomes, species distribution, and regional epidemiology, enabling more informed decision-making and benchmarking.
Growth in the nontuberculous mycobacterial infections market is driven by several factors.
Increasing prevalence of NTM infections, especially among aging and immunocompromised populations, is expanding patient pools and clinical awareness. Advances in molecular diagnostics are enabling faster and more accurate species identification and resistance profiling. Introduction of novel antimycobacterial drugs and inhaled delivery systems is offering alternatives to standard therapies. Emergence of multidisciplinary care models supported by telehealth and digital adherence tools is improving long-term treatment success. Finally, formation of patient registries and growing research into NTM epidemiology and therapeutics are fostering treatment innovation and adoption of best practices by healthcare providers.
SCOPE OF STUDY:
The report analyzes the Nontuberculous Mycobacterial Infections market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Drug Type (Clarithromycin, Azithromycin, Rifampin, Rifabutin, Other Drug Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 36 Featured) -
Abbott Laboratories
Astellas Pharma Inc.
AstraZeneca PLC
Bayer AG
BioMarin Pharmaceutical Inc.
Bristol Myers Squibb
Cipla Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Insmed Incorporated
Janssen (Johnson & Johnson)
MannKind Corporation
Merck & Co. Inc.
Novartis AG
Paratek Pharmaceuticals Inc.
Pfizer Inc.
RedHill Biopharma Ltd.
Sanofi S.A.
Spero Therapeutics Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Vertex Pharmaceuticals Inc.
Zydus Lifesciences Ltd.
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Nontuberculous Mycobacterial Infections - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Nontuberculous Mycobacterial (NTM) Infections Drives Demand for Targeted Diagnostics and Therapies
Increased Awareness and Improved Diagnostic Capabilities Lead to Higher Detection Rates of NTM Lung Disease
Expansion of At-Risk Populations, Including the Elderly and Immunocompromised, Fuels Market Demand
Advancements in Molecular and Culture-Based Diagnostic Tools Enhance Early Identification and Species Differentiation
Growing Prevalence of Underlying Pulmonary Conditions Like COPD and Bronchiectasis Spurs NTM Management Needs
Surge in Macrolide-Resistant Strains Throws the Spotlight on Development of New Antimicrobial Regimens
Emerging Role of Biofilm Research and Intracellular Pathogen Studies Improves Therapeutic Targeting
Regulatory Push for Drug Development in Rare and Refractory Infections Encourages Investment in NTM Therapies
Increasing Use of Combination Antibiotic Therapies Promotes Long-Term Treatment Management Strategies
Globalization of Airborne Infectious Risk Awareness Promotes Proactive Screening and Treatment Guidelines
Integration of Next-Generation Sequencing and Genomic Typing Enhances Pathogen Surveillance and Resistance Mapping
Rise in Hospital-Acquired and Post-Surgical Infections Linked to NTM Underscores Need for Enhanced Prevention
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Nontuberculous Mycobacterial Infections Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Nontuberculous Mycobacterial Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 4: World 16-Year Perspective for Nontuberculous Mycobacterial Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Clarithromycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Clarithromycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 7: World 16-Year Perspective for Clarithromycin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Azithromycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Azithromycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 10: World 16-Year Perspective for Azithromycin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Rifampin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Rifampin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 13: World 16-Year Perspective for Rifampin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Rifabutin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Rifabutin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 16: World 16-Year Perspective for Rifabutin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 22: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 25: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 28: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 30: USA Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 31: USA 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: USA Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 34: USA 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
CANADA
TABLE 35: Canada Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 37: Canada 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 40: Canada 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
JAPAN
Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 43: Japan 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 44: Japan Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 46: Japan 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
CHINA
Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 47: China Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: China Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 49: China 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 50: China Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: China Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 52: China 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
EUROPE
Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 53: Europe Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Nontuberculous Mycobacterial Infections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 55: Europe 16-Year Perspective for Nontuberculous Mycobacterial Infections by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 58: Europe 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 61: Europe 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
FRANCE
Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 62: France Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: France Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 64: France 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 65: France Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: France Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 67: France 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
GERMANY
Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 68: Germany Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 70: Germany 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 71: Germany Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Germany Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 73: Germany 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
ITALY
TABLE 74: Italy Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 76: Italy 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 77: Italy Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: Italy Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 79: Italy 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
UNITED KINGDOM
Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 80: UK Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: UK Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 82: UK 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 83: UK Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: UK Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 85: UK 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
SPAIN
TABLE 86: Spain Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 88: Spain 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 89: Spain Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Spain Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 91: Spain 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
RUSSIA
TABLE 92: Russia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 94: Russia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 95: Russia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Russia Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 97: Russia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
REST OF EUROPE
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Rest of Europe Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 103: Rest of Europe 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
ASIA-PACIFIC
Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Nontuberculous Mycobacterial Infections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Nontuberculous Mycobacterial Infections by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: Asia-Pacific Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 112: Asia-Pacific 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
AUSTRALIA
Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 113: Australia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 115: Australia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 116: Australia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: Australia Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 118: Australia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
INDIA
Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 119: India Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: India Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 121: India 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 122: India Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: India Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 124: India 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
SOUTH KOREA
TABLE 125: South Korea Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 127: South Korea 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 128: South Korea Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: South Korea Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 130: South Korea 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Rest of Asia-Pacific Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
LATIN AMERICA
Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 137: Latin America Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Nontuberculous Mycobacterial Infections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Nontuberculous Mycobacterial Infections by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 142: Latin America 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 143: Latin America Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Latin America Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 145: Latin America 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
ARGENTINA
TABLE 146: Argentina Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 148: Argentina 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 149: Argentina Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Argentina Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 151: Argentina 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
BRAZIL
TABLE 152: Brazil Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 154: Brazil 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 155: Brazil Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Brazil Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 157: Brazil 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
MEXICO
TABLE 158: Mexico Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 160: Mexico 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 161: Mexico Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Mexico Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 163: Mexico 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 166: Rest of Latin America 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: Rest of Latin America Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 169: Rest of Latin America 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
MIDDLE EAST
Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 170: Middle East Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Nontuberculous Mycobacterial Infections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Nontuberculous Mycobacterial Infections by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 175: Middle East 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 176: Middle East Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 178: Middle East 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
IRAN
TABLE 179: Iran Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 181: Iran 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 182: Iran Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: Iran Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 184: Iran 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
ISRAEL
TABLE 185: Israel Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 187: Israel 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 188: Israel Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: Israel Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 190: Israel 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
SAUDI ARABIA
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 193: Saudi Arabia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: Saudi Arabia Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 196: Saudi Arabia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 197: UAE Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 199: UAE 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 200: UAE Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: UAE Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 202: UAE 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 205: Rest of Middle East 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Rest of Middle East Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 208: Rest of Middle East 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
AFRICA
Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 209: Africa Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 211: Africa 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
TABLE 212: Africa Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 213: Africa Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 214: Africa 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030